This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
25
oral tablet
oral tablet
Vanda Investigational Site
Springfield, Missouri, United States
Bioequivalence between VHX-896 tablets relative to iloperidone tablets
as measured by plasma concentrations
Time frame: 96 hours
Assessment of Safety and Tolerability of a single dose of VHX-896
As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs
Time frame: 17 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.